



**PATENT APPLICATION**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Dominique ROECKLIN et al.

Group Art Unit: 1634

Application No.: 10/030,937

Examiner: J. MARTINELL

Filed: May 24, 2002

Docket No.: 111664

For: USE OF A POLYPEPTIDE FOR DETECTING, PREVENTING OR TREATING A  
PATHOLOGICAL CONDITION ASSOCIATED WITH A DEGENERATIVE,  
NEUROLOGICAL OR AUTOIMMUNE DISEASE

**REQUEST FOR ACKNOWLEDGMENT OF  
CONSIDERATION OF DISCLOSED INFORMATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Information Disclosure Statements with Forms PTO-1449 were filed in the above-captioned patent application on June 4, 2002, and June 11, 2002. Copies of the stamped postcard receipts are attached. Applicants have not yet received back from the Examiner copies of the Forms PTO-1449 initialed to acknowledge the fact that the Examiner has considered the cited disclosed information.

The Examiner is requested to initial and return to the undersigned a copy of the subject Forms PTO-1449. For the convenience of the Examiner, copies of the Information Disclosure Statements and references cited therein are attached.

With regard to the references that are in a language other than English, as indicated in the Information Disclosure Statement filed June 4, 2002, references 1-8 were cited in a counterpart foreign application. An English-language version of the Search Report listing these references is attached. In addition, a concise explanation of the relevance of reference 86 is attached.

Should there be any questions concerning this communication, please telephone the undersigned at the number set forth below.

Respectfully submitted,



William P. Berridge  
Registration No. 30,024

Melanie L. McCollum  
Registration No. 40,085

WPB:MLM/jam

Attachments:


June 4 and 11, 2002 Postcard Receipts  
June 4 and 11, 2002 Information Disclosure Statements w/Forms PTO-1449  
References Cited therein  
Search Report  
Concise Explanation of Reference 86

Date: February 1, 2006

**OLIFF & BERRIDGE, PLC**  
**P.O. Box 19928**  
**Alexandria, Virginia 22320**  
**Telephone: (703) 836-6400**

**DEPOSIT ACCOUNT USE  
AUTHORIZATION**

Please grant any extension  
necessary for entry;  
Charge any fee due to our  
Deposit Account No. 15-0461



**PTO RECEIPT FOR FILING OF PAPERS**

The following papers have been filed:

IDS pto 1449 w/ 89 refs & Search Report

**Name of Applicant:** Dominique ROECKLIN et al.

**Serial No.:** 10/030,937

**Atty. File No.:** 111664

**Title (New Cases):**

**Sender's Initials:** WPB/mlb

283/35



**PATENT OFFICE DATE STAMP**

**COPY TO BE STAMPED BY PATENT OFFICE  
AND RETURNED BY MESSENGER**



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Dominique ROECKLIN et al.

Application No.: 10/030,937

Filed: May 24, 2002

Docket No.: 111664

For: USE OF POLYPEPTIDE FOR DETECTING, PREVENTING OR TREATING A  
PATHOLOGICAL CONDITION ASSOCIATED WITH A DEGENERATIVE,  
NEUROLOGICAL OR AUTOIMMUNE DISEASE

INFORMATION DISCLOSURE STATEMENT


Director of the U.S. Patent and Trademark Office  
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- ☒ 2. Relevance of the non-English language and English language references 4, 6, 9-88 are discussed in the present specification.
- ☒ 3. References 1-8 -were cited in a counterpart foreign application. An English language version of the foreign search report is attached for the Examiner's information.

Respectfully submitted,

  
William P. Berridge  
Registration No. 30,024

Melanie L. Mealy  
Registration No. 40,085

WPB:PAC/mlb  
Date: June 4, 2002

OLIFF & BERRIDGE, PLC  
P.O. Box 19928  
Alexandria, Virginia 22320  
Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE  
AUTHORIZATION  
Please grant any extension  
necessary for entry;  
Charge any fee due to our  
Deposit Account No. 15-0461



Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 111664		APPLICATION NO. 10/030,937	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				APPLICANTS Dominique ROECKLIN et al.			
				FILING DATE May 24, 2002			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
	1	5,876,954	03/02/1999	Perron et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
	2	JP A 8-308582	11/26/1996	Japan			
	3	CA 2,214,843	04/30/1999	Canada			
	4	WO 97/33466	09/18/1997	Wipo			
	5	WO 90/07712	07/12/1990	Wipo			
	6	WO 98/11439	03/19/1998	Wipo			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	7	Rieger et al., "Un facteur gliotoxique et la sclerose en plaques", C.R. Acad. Sci. Paris, Sciences de la vie/Life sciences, XP 000602023, pp. 343-350, 1996					
	8	Kisilevsky et al., "Arresting amyloidosis <i>in vivo</i> using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease", Nature Medicine, Vol. 1, No. 2, pp.143-148, 1995					
	9	Conzelmann et al., "Purification and Characterization of an Activator Protein for the Degradation of Glycolipids GM <sub>2</sub> and GA <sub>2</sub> by Hexosaminidase A", Hoppe-Seyler's Z. Physiol. Chem., pp. 1837-1849, 1979					
	10	Hitomi et al., "A novel calcium-binding protein in amniotic fluid, CAAF1: its molecular cloning and tissue distribution", Journal of Cell Science, pp. 805-815, 1996					
	11	Raftery et al., "Isolation of the murine S100 protein MRP14 (14 kDa migration-inhibitory-factor-related protein) from activated spleen cells: characterization of post-translational modifications and zinc binding", Biochem J., pp. 285-293, 1996					
	12	Kase et al., "Only sphingolipid activator protein B (SAP-B or saposin B) stimulates the degradation of globotriaosylceramide by recombinant human lysosomal $\alpha$ -galactosidase in a detergent-free liposomal system", FEBS Letters, pp. 74-76, 1996					
	13	Bierfreund et al., "Recombinant GM2-Activator Protein Stimulates <i>In Vivo</i> Degradation of GA2 in GM2 Gangliosidosis AB Variant Fibroblasts But Exhibits No Detectable Binding of GA2 in an <i>In Vitro</i> Assay", Neurochemical Research, Vol. 24, No. 2, pp. 295-300, 1999					
	14	Longbottom et al., "Subunit structure of calgranulins A and B obtained from sputum, plasma, granulocytes and cultured epithelial cells", Biochimica et Biophysica Acta, pp. 215-222, 1992					
	15	Raftery et al., "Overexpression, Oxidative Refolding, and Zinc Binding of Recombinant Forms of the Murine S100 Protein MRP14 (S100A9)", Protein Expression and Purification, pp. 228-235, 1999					
	16	Klempt et al., "The heterodimer of the Ca <sup>2+</sup> -binding proteins MRP8 and MRP14 binds arachidonic acid", FEBS Letters, pp. 81-84, 1997					

Date: June 4, 2002



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
		et al., "Colorimetric diagnosis of prolonged bluetongue viremia in sheep, using an enzyme-linked oligonucleotide sorbent assay of amplified viral nucleic acids", Am J Vet Res, Vol. 54, No. 12, pp. 2021-2026, 1993
18	Toes et al., "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion", Proc. Natl. Acad. Sci., Vol. 94, pp. 14660-14665, 1997	
19	Bird et al., "Single-Chain Antigen-Binding Proteins", Science Reports, pp. 423-426, 1988	
20	Arakawa et al., "Cloning and Sequencing of the V <sub>H</sub> and V <sub>L</sub> Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody", J. Biochem, pp. 657-662, Vol. 120, No. 3, 1996	
21	Chaudhary et al., "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin", Letters to Nature, Vol. 339, pp. 394-397, 1989	
22	Behr et al., "Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA", Proc. Natl. Acad. Sci, Vol. 86, pp. 6982-6986, 1989	
23	Debrick et al., "Macrophages As Accessory Cells For Class I MHC-Restricted Immune Responses", The Journal of Immunology, Vol. 147, No. 9, pp. 2846-2851, 1991	
24	Kovacsovics-Bankowski et al., "A Phagosome-to-Cytosol Pathway for Exogenous Antigens Presented on MHC Class I Molecules", Science Reports, Vol. 267, pp. 243-246, 1995	
25	Kovacsovics-Bankowski et al., "Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages", Proc. Natl. Acad. Sci, Vol. 90, pp. 4942-4946, 1993	
26	Racoosin et al., "M-CSF-induced macropinocytosis increases solute endocytosis but not receptor-mediated endocytosis in mouse macrophages", Journal of Cell Science, pp. 867-880, 1992	
27	Finke et al., "Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene", Gene Therapy, pp. 31-39, 1998	
28	Haensler et al., "Polyamidoamine Cascade Polymers Mediate Efficient Transfection of Cells in Culture", Bioconjugate Chem., pp. 372-379, 1993	
29	Deo et al., "Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies", Immunology Today, Vol. 18, pp. 127-135, 1997	
30	Pessino et al., "Molecular Cloning of NKp46: A Novel Member of the Immunoglobulin Superfamily Involved in Triggering of Natural Cytotoxicity", J. Exp. Med, Vol. 188, No. 5, pp. 953-960, 1998	
31	Kawano et al., "Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells", Proc. Natl. Acad. Sci., Vol. 95, pp. 5690-5693, 1998	
32	McCoy et al., "Pulmonary Inflammation Induced by Incomplete or Inactivated Adenoviral Particles", Human Gene Therapy, pp. 1553-1560, 1995	
33	Cotten et al., "Non-viral approaches to gene therapy", Current Biology, pp. 705-710, 1993	
34	Felgner et al., "Cationic liposome-mediated transfection", Nature, Vol. 337, pp. 387-388, 1989	
35	Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", Proc. Natl. Acad. Sci, Vol. 84, pp. 7413-7417, 1987	
36	Felgner et al., "Cationic Lipid-Mediated Delivery of Polynucleotides", Methods, pp. 67-75, 1993	
37	Gao et al., "A Novel Cationic Liposome Reagent For Efficient Transfection of Mammalian Cells", Biochemical and Biophysical Research Communication, Vol. 179, No. 1, pp. 280-285, 1991	
38	Groettrup et al., "Peptide antigen production by the proteasome: complexity provides efficiency", Immunology Today, Vol. 17, No 9, pp. 429-435, 1996	
39	Polydefkis et al., "Anchor Sequence-Dependent Endogenous Processing of Human Immunodeficiency Virus 1 Envelope Glycoprotein gp160 For CD4+ T Cell Recognition", J. Exp Med, Vol. 171, pp. 875-887, 1990	
40	Sallusto et al., "Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class II Compartment: Downregulation by Cytokines and Bacterial Products", J. Exp. Med, Vol. 182, pp. 389-400, 1995	
41	Melero et al., "Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway", Eur. J. Immunol., pp. 1116-1121, 1998	
42	Whitton et al., "A "String-of-Beads" Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge", Journal of Virology, vol. 67, No. 1, pp. 348-352, 1993	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
43	Svensson et al., "Bone Marrow-Derived Dendritic Cells Can Process Bacteria for MHC-I and MHC-II Presentation to T Cells", The Journal of Immunology, pp. 4229-4236, 1997
44	Norbury et al., "Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells", Eur. J. Immunol., pp. 280-288, 1997
45	Routledge et al., "A humanized monovalent CD3 antibody which can activate homologous complement", Eur. J. Immunol, pp. 2717-2725, 1991
46	Sousa et al., "Phagocytosis of Antigens by Langerhans Cells In Vitro", J. Exp. Med, Vol. 178, pp. 509-519, 1993
47	Klein et al., "Sphingolipid Activator Protein D ( <i>sap</i> -D) Stimulates the Lysosomal Degradation of Ceramide <i>In Vivo</i> ", Biochemical and Biophysical Research Communications, Vol. 200, No. 3, pp. 1440-1448, 1994
48	Murao et al., "A Protein Complex Expressed during Terminal Differentiation of Monomyelocytic Cells Is an Inhibitor of Cell Growth", Cell Growth & Differentiation, Vol. 1, pp. 447-454, 1990
49	Murthy et al., "In Vitro Candidastatic Properties of the Human Neutrophil Calprotectin Complex", Journal of Immunology, Vol. 151, No. 11, pp. 6291-6301, 1993
50	Murdoch et al., "Primary Structure of the Human Heparan Sulfate Proteoglycan from Basement Membrane (HSPG2/Perlecan), The Journal of Biological Chemistry, Vol. 267, No. 12, pp. 8544-8557, 1992
51	Zaltash et al., "Secondary structure and limited proteolysis give experimental evidence that the precursor of pulmonary surfactant protein B contains three saposin-like domains", FEBS Letters, pp. 1-4, 1998
52	Lagasse et al., "Cloning and Expression of Two Human Genes Encoding Calcium-Binding Proteins That Are Regulated during Myeloid Differentiation", Molecular and Cellular Biology, Vol. 8, No. 6, pp. 2402-2410, 1988
53	Kleinschmidt et al., "Complete Amino-Acid Sequence of the Naturally Occuring A <sub>2</sub> Activator Protein for Enzymic Sphingomyelin Degradation: Identity to the Sulfatide Activator Protein (SAP-1)", Biol. Chem. Hoppe-Seyler, Vol. 369, pp. 1361-1365, 1988
54	O'Brein et al., "Saposin proteins: structure, function, and role in human lysosomal storage disorders", The FASEB Journal, Vol. 5, pp. 301-308, 1991
55	Roda et al., "Production of a High-Titer Antibody to Bile Acids", Journal of Steroid Biochemistry, Vol. 13, pp. 449-454, 1980
56	Scheibenbogen et al., "A Sensitive ELISPOT Assay for Detection of CD8+ T Lymphocytes Specific for HLA Class I-binding Peptide Epitopes Derived from Influenza Proteins in the Blood of Healthy Donors and Melanoma Patients", Clinical Cancer Research, Vol. 3, pp. 221-226, 1997
57	Misasi et al., "Colocalization and Complex Formation Between Prosaposin and Monosialoganglioside GM3 in Neural Cells", Journal of Neurochemistry, Vol. 71, No. 6, pp. 2313-2321, 1998
58	Versteeg, "NK cells and T cells: mirror images?", Immunology Today, Vol. 13, No. 7, pp. 244-247, 1992
59	George et al., "Disease susceptibility, transplantation and the MHC", Immunology Today, Vol. 16, No. 5, pp. 209-211, 1995
60	Brittenden et al., "Natural Killer Cells and Cancer", Cancer, Vol. 77, No. 7, pp. 1226-1243, 1996
61	Blazar et al., "Anti-CD3εF(ab') <sub>2</sub> Fragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen <sup>1,2</sup> ", The Journal of Immunology, pp. 5821-5833, 1997
62	McLachlan et al., "Evaluation in vitro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy", Gene Therapy, pp. 614-622, 1995
63	Behr et al., "Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA", Proc. Natl. Acad. Sci., Vol. 96, pp. 6982-6986, 1989
64	Waring et al., "Porcine Cerebroside Sulfate Activator (Saposin B) Secondary Structure: CD, FTIR, and NMR Studies", Molecular Genetics and Metabolism, pp. 14-25, 1998
65	Anderson et al., "Antibodies to DNA", BioEssays, Vol. 8, No. 2, pp. 69-75, 1988
66	Kohler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature, Vol. 256, pp. 495-497, 1975
67	Yajima et al., "SiC and Si <sub>3</sub> N <sub>4</sub> sintered bodies with new borodiphenylsiloxane polymers as binder", Nature, Vol. 266, pp. 522-524, 1977

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

68	Lee et al., "Functional groups on 'Z' DNA recognized by monoclonal antibodies", FEBS Letters, Vol. 168, No. 2, pp. 303-306, 1984
69	Malfoy et al., "Interaction between Antibodies to Z-Form Deoxyribonucleic Acid and Double-Stranded Polynucleotides", Biochemistry, pp. 5463-5467, 1982
70	Traincard et al., "Calibration of target amounts of DNA in hybridization experiments using monoclonal anti-nucleoside antibodies", Molecular and Cellular Probes, pp. 27-38, 1989
71	Traincard et al., "Monoclonal anti-nucleoside antibodies Characterization and application in an enzyme immunoassay of single-stranded DNA", Journal of Immunological Methods, pp. 83-91, 1989
72	Cros et al, "Monoclonal antibodies targeted to $\alpha$ -oligonucleotides. Characterisation and application in nucleic acid detection", Nucleic Acids Research, Vol. 22, No. 15, pp. 2951-2957, 1994
73	Li et al., "Presence of Activator Proteins for the Enzymic Hydrolysis of $G_{M1}$ and $G_{M2}$ Gangliosides in Normal Human Urine", Am J Hum Genet, pp. 629-634, 1983
74	Li et al., "A Protein Activator for the Enzymic Hydrolysis of $G_{M2}$ Ganglioside", The Journal of Biological Chemistry, Vol. 256, No. 12, p. 6234-6240, 1981
75	Li et al., "An Activator Stimulating the Enzymic Hydrolysis of Sphingoglycolipids", The Journal of Biological Chemistry, Vol. 251, No. 4, pp. 1159-1163, 1976
76	Kishimoto et al., "Saposins: structure, function, distribution, and molecular genetics", Journal of Lipid Research, Vol. 33, pp. 1255-1267, 1992
77	Mallet et al., "Enzyme-Linked Oligosorbent Assay for Detection of Polymerase Chain Reaction-Amplified Human Immunodeficiency Virus Type 1", Journal of Clinical Microbiology, Vol. 31, No. 6, pp. 1444-1449, 1993
78	Saintigny et al., "Differential Expression of Calgranulin A and B in Various Epithelial Cell Lines and Reconstructed Epidermis", The Journal of Investigative Dermatology, pp. 639-644, 1992
79	Goebeler et al., "The monoclonal antibody MAC387 detects an epitope on the calcium-binding protein MRP14", Journal of Leukocyte Biology, Vol. 55, pp. 259-261, 1994
80	Qi et al., "Functional Human Saposins Expressed in <i>Escherichia coli</i> ", The Journal of Biological Chemistry, Vol. 269, No. 24, pp. 16746-16753, 1994
81	Yuziuk et al, "Specificity of Mouse $G_{M2}$ Activator Protein and $\beta$ -N-Acetylhexosaminidase A and B", The Journal of Biological Chemistry, Vol. 273, No. 1, pp. 66-72, 1998
82	DeGasperi et al., "Isolation and characterization of an activator protein for the hydrolysis of ganglioside $G_{M2}$ from the roe of stiped mullet ( <i>Mugil cephalus</i> )", Biochem J. , pp. 777-783, 1989
83	Vogel et al, "Identity of the Activator Proteins for the Enzymatic Hydrolysis of Sulfatide, Ganglioside $G_{M1}$ , and Globotriaosylceramide", Archives of Biochemistry and Biophysics, Vol. 259, No. 2, pp. 627-638, 1987
84	Hirabayashi et al., "The Protein Activator Specific for the Enzymic Hydrolysis of $G_{M2}$ Ganglioside in Normal Human Brain and Brains of Three Types of $G_{M2}$ Gangliosidosis", Journal of Neurochemistry, Vol. 40, No. 1, pp. 168-175, 1983
85	Bos et al., "Copurification of P6, MRP8, and MRP14 from Human Granulocytes and Separation of Individual Proteins <sup>1</sup> ", Protein Expression and Purification, pp. 313-318, 1998
86	"Les Transcrits Subissent une Maturation Nucleaire Qui Debutte Avant Que La Transcription Ne Soit Achevee", Du Genotype Au Phenotype, pp. 73-77
87	"Molecular cloning-A laboratory manual", CHS Laboratory, Cold Spring, 1982
88	Remington's Pharmaceutical Sciences, Mack Publishing, 16 <sup>th</sup> Edition, 1980
89	Li et al., "Characterization of a Nonspecific Activator Protein for the Enzymatic Hydrolysis of Glycolipids*", Journal of Biological Chemistry, Vol. 263, No. 14, pp. 6588-6591, 1988

EXAMINER

DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date: June 4, 2002



## Concise explanation of Reference 86 of the 6/4/02 IDS


This document presents the general features of messenger RNA (mRNA) functions. In the first paragraphs, a brief description of mRNA characteristics is made: methylated 5' cap, 3' polyadenylation, metastability and stabilisation by proteins, etc...

Follows a description of splicing processes. mRNA are primarily transcribed directly from DNA with exons and introns. Then, specific sequence tags flanking introns allow the RNA to "hairpin" the intronic parts. These hairpins are subsequently eliminated by a very complex enzymatic cascade involving proteins and small nuclear RNAs (snRNA) that altogether form a catalytic complex in the cell nucleus, called spliceosome. After these intronic hairpins are cut, sequences of contiguous are reassembled by ligation, thus providing a "mature" mRNA (without introns) now ready to cross the nucleus membrane into the endoplasmic reticulum for translation into protein at the ribosomal level.

The last paragraphs provide details on special "spliceosome-like" structures that have also been identified in certain cell types and explain the notion of alternative splicing. Indeed, introns may be excised together with certain exons in a variable manner, apparently controlled by the intracellular concentration of a regulatory protein that differs amongst cell types and conditions. This "alternative splicing" provides "alternatives" to the full-length mature mRNA (with all exons) and can thus generate mRNAs encoding different proteins from the same parental "primary mRNA". This phenomenon is used in eukaryotes but can also be found in viruses, with alternative splicing sites located within viral genes open reading frames or determining the expression of several unrelated protein by producing codon initiation in two of three successive reading frames within the viral RNA sequence.

Therefore, a single gene may encode several proteins with or without common domains (from common exons) through this mechanism of mRNA alternative splicing.

*Certified in honest agreement with the original text, by the author of the above-written summary, Hervé Perron.*



**PTO RECEIPT FOR FILING OF PAPERS**

The following papers have been filed:

IDS pto 1449 w/ 2 refs.

**Name of Applicant:** Dominique ROECKLIN et al.

**Serial No.:** 10/030,937

**Atty. File No.:** 111664

**Title (New Cases):**

**Sender's Initials:** WPB/mlb

288/43



**PATENT OFFICE DATE STAMP**

**COPY TO BE STAMPED BY PATENT OFFICE  
AND RETURNED BY MESSENGER**



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Dominique ROECKLIN et al.

Application No.: 10/030,937

Filed: May 24, 2002

Docket No.: 111664

For: USE OF POLYPEPTIDE FOR DETECTING, PREVENTING OR TREATING A  
PATHOLOGICAL CONDITION ASSOCIATED WITH A DEGENERATIVE,  
NEUROLOGICAL OR AUTOIMMUNE DISEASE

INFORMATION DISCLOSURE STATEMENT

Director of the U.S. Patent and Trademark Office  
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- ☒ 2. Relevance of the non-English language and English language references 1 and 2 is discussed in the present specification.

Respectfully submitted,

William P. Berridge  
Registration No. 30,024

Reg No  
40085


Thomas J. Pardini  
Registration No. 30,411

WPB:TJP/mlb  
Date: June 11, 2002

**OLIFF & BERRIDGE, PLC**  
**P.O. Box 19928**  
**Alexandria, Virginia 22320**  
**Telephone: (703) 836-6400**

**DEPOSIT ACCOUNT USE  
AUTHORIZATION**

Please grant any extension  
necessary for entry;  
Charge any fee due to our  
Deposit Account No. 15-0461

Sheet 1 of 1Form PTO-1449  
(REV. 8-83)US Dept. of Commerce  
PATENT & TRADEMARK OFFICEATTY DOCKET NO.  
111664APPLICATION NO.  
10/030,937

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS  
Dominique ROECKLIN et al.FILING DATE  
May 24, 2002

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	1	Furst et al., "The complete amino-acid sequences of human ganglioside GM2 activator protein and cerebroside sulfate activator protein", Eur. J. Biochem, pp. 709-714, 1990
	2	Yang et al., "Monoclonal T Cells Identified in Early NOD Islet Infiltrates", Immunity, Vol. 4, pp. 189-194, 1996

EXAMINER

DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date: June 11, 2002